...
首页> 外文期刊>Current Cardiology Reports >Transcatheter Valve-in-Valve Therapies: Patient Selection, Prosthesis Assessment and Selection, Results, and Future Directions
【24h】

Transcatheter Valve-in-Valve Therapies: Patient Selection, Prosthesis Assessment and Selection, Results, and Future Directions

机译:经导管瓣膜治疗:患者选择,假体评估和选择,结果和未来方向

获取原文
获取原文并翻译 | 示例

摘要

The development of transcatheter valve implantations (TAVI) has induced profound changes in the treatment of valvular heart disease over the past decade. At the same time, due to excellent clinical results, bioprostheses continuously outperformed mechanical prostheses. The increasing number of elderly patients has led to numerous patients presenting with deteriorated bioprostheses needing reoperation. In selected high-risk patients or patients with unreasonable surgical risk, valve-in-valve TAVI has advanced to a viable alternative to conventional redo surgery. High procedural success, good hemodynamics and acceptable clinical results were reported up until now. Valve-in-valve TAVI seems to be safe and effective in treatment of deteriorated valve prostheses in high-risk patients. The valve-in-valve concept presents the next step toward an individual treatment strategy for patients at prohibitive risk for conventional surgery. Present studies were reviewed with special concern to patient selection, prosthesis assessment, device selection, clinical outcome and technical challenging aspects as well.
机译:在过去的十年中,经导管瓣膜植入术(TAVI)的发展已引起瓣膜性心脏病治疗的深刻变化。同时,由于出色的临床效果,生物假体持续优于机械假体。老年患者数量的增加导致许多患者的生物假体质量下降,需要再次手术。对于某些高危患者或手术风险不合理的患者,瓣膜内TAVI已发展成为常规重做手术的可行替代方案。迄今为止,已有报道称,该方法具有很高的手术成功率,良好的血液动力学和可接受的临床效果。瓣膜瓣膜TAVI在治疗高危患者的瓣膜假体方面似乎是安全有效的。瓣膜阀概念为有常规手术高风险的患者提供了迈向个性化治疗策略的下一步。审查了当前的研究特别关注患者选择,假体评估,设备选择,临床结果和技术挑战性方面。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号